Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections

Trends in Microbiology

Volumn 24, Issue 5, 2016, Pages 327-337

  Winstanley, Craig ^a   O'Brien, Siobhan ^b   Brockhurst, Michael A ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Adaptation; Cystic fibrosis; Evolution; Population biology; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL DIVISION; CYSTIC FIBROSIS; DISEASE TRANSMISSION; DNA REPAIR; EVOLUTIONARY ADAPTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; LUNG INFECTION; NONHUMAN; PHENOTYPE; POPULATION ABUNDANCE; POPULATION GENETICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; REVIEW; RNA TRANSLATION; ADAPTATION; CHRONIC DISEASE; EVOLUTION; GENETIC VARIATION; GENETICS; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTION;

ADAPTATION, BIOLOGICAL; BIOLOGICAL EVOLUTION; CHRONIC DISEASE; CYSTIC FIBROSIS; GENETIC VARIATION; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRULENCE FACTORS;

EID: 84959309866     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2016.01.008     Document Type: Review

References (84)

1. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 2012, 18:509-519.
2. Lyczak J.B., et al. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2000, 2:1051-1060.
3. Stover C.K., et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406:959-964.
4. Silby M.W., et al. Pseudomonas genomes: diverse and adaptable. FEMS Microbiol. Rev. 2011, 35:652-680.
5. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 2014, 11:CD004197.
6. Burns J.L., Rolain J.M. Culture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity?. J. Cyst. Fibrosis 2014, 13:1-9.
7. Brocker C., et al. The role of hyperosmotic stress in inflammation and disease. Biomol. Concepts 2012, 3:345-364.
8. Hector A., et al. Oxidative stress in cystic fibrosis lung disease: an early event, but worth targeting?. Eur. Respir. J. 2014, 44:17-19.
9. Wood S.R., et al. Nitrosative stress inhibits production of the virulence factor alginate in mucoid Pseudomonas aeruginosa. Free Radic. Res. 2007, 41:208-215.
10. Andersson D.I., Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat. Rev. Microbiol. 2014, 12:465-478.
11. Fodor A.A., et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 2012, 7:e45001.
12. Lopes S.P., et al. Microbiome in cystic fibrosis: shaping polymicrobial interactions for advances in antibiotic therapy. Crit. Rev. Microbiol. 2014, 41:353-565.
13. Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 1996, 60:539-574.
14. Bjarnsholt T., et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 2009, 44:547-558.
15. Barth A.L., Pitt T.L. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. J. Med. Microbiol. 1996, 45:110-119.
16. Mahenthiralingam E., et al. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect. Immun. 1994, 62:596-605.
17. Oliver A., et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1254.
18. Doring G., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000, 16:749-767.
19. Breidenstein E.B., et al. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011, 19:419-426.
20. Hoffman L.R., et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J. Cyst. Fibrosis 2009, 8:66-70.
21. Balasubramanian D., et al. Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator. Pathog. Dis. 2015, 73:1-14.
22. Nguyen D., Singh P.K. Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8305-8306.
23. Winstanley C., Fothergill J.L. The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections. FEMS Microbiol. Lett. 2009, 290:1-9.
24. Smith E.E., et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8487-8492.
25. Yang L., et al. Evolutionary dynamics of bacteria in a human host environment. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7481-7486.
26. Bragonzi A., et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am. J. Respir. Crit. Care Med. 2009, 180:138-145.
27. Cramer N., et al. Microevolution of the major common Pseudomonas aeruginosa clones C and PA14 in cystic fibrosis lungs. Environ. Microbiol. 2011, 13:1690-1704.
28. Hoboth C., et al. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 2009, 200:118-130.
29. Marvig R.L., et al. Within-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients. BMC Microbiol. 2015, 15:218.
30. Marvig R.L., et al. Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet. 2013, 9:e1003741.
31. Marvig R.L., et al. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat. Genet. 2015, 47:57-64.
32. Marvig R.L., et al. Within-host evolution of Pseudomonas aeruginosa reveals adaptation toward iron acquisition from hemoglobin. mBio 2014, 5. e00966-14.
33. Folkesson A., et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 2012, 10:841-851.
34. Marvig R.L., et al. Evolutionary insight from whole-genome sequencing of Pseudomonas aeruginosa from cystic fibrosis patients. Future Microbiol. 2015, 10:599-611.
35. Balasubramanian D., et al. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res. 2013, 41:1-20.
36. Fothergill J.L., et al. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur. Respir. J. 2012, 40:227-238.
37. Winstanley C., et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res. 2009, 19:12-23.
38. Diaz Caballero J., et al. Selective sweeps and parallel pathoadaptation drive Pseudomonas aeruginosa evolution in the cystic fibrosis lung. mBio 2015, 6. e00981-15.
39. Wong A., et al. Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet. 2012, 8:e1002928.
40. Jansen G., et al. Evolutionary transition from pathogenicity to commensalism: global regulator mutations mediate fitness gains through virulence attenuation. Mol. Biol. Evol. 2015, 32:2883-2896.
41. McElroy K.E., et al. Strain-specific parallel evolution drives short-term diversification during Pseudomonas aeruginosa biofilm formation. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1419-E1427.
42. Foweraker J.E., et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 2005, 55:921-927.
43. Mowat E., et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 2011, 183:1674-1679.
44. Darch S.E., et al. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection. Sci. Rep. 2015, 5:7649.
45. Workentine M.L., et al. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 2013, 8:e60225.
46. Fothergill J.L., et al. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J. Med. Microbiol. 2010, 59:472-481.
47. Ashish A., et al. Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis. J. Cyst. Fibrosis 2013, 12:790-793.
48. Clark S.T., et al. Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis. Sci. Rep. 2015, 5:10932.
49. Wilder C.N., et al. Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect. Immun. 2009, 77:5631-5639.
50. Hurley M.N., et al. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibrosis 2012, 11:288-292.
51. Smith A.L., et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123:1495-1502.
52. Chung J.C., et al. Genomic variation among contemporary Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. J. Bacteriol. 2012, 194:4857-4866.
53. Williams D., et al. Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections. Am. J. Resp. Crit. Care Med. 2015, 191:775-785.
54. Markussen T., et al. Environmental heterogeneity drives within-host diversification and evolution of Pseudomonas aeruginosa. mBio 2014, 5. e01592-14.
55. Jorth P., et al. Regional isolation drives bacterial diversification within cystic fibrosis lungs. Cell Host Microbe 2015, 18:307-319.
56. Dettman J.R., et al. Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:21065-21070.
57. Williams D., et al. Refined analyses suggest that recombination is a minor source of genomic diversity in Pseudomonas aeruginosa chronic cystic fibrosis infections. Microb. Genom. 2016, Published online January 18, 2016. 10.1099/mgen.0.000051.
58. Boles B.R., et al. Self-generated diversity produces "insurance effects" in biofilm communities. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16630-16635.
59. Boles B.R., Singh P.K. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12503-12508.
60. Traverse C.C., et al. Tangled bank of experimentally evolved Burkholderia biofilms reflects selection during chronic infections. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E250-E259.
61. Wright E.A., et al. Sub-inhibitory concentrations of some antibiotics can drive diversification of Pseudomonas aeruginosa populations in artificial sputum medium. BMC Microbiol. 2013, 13:170.
62. Hutschala D., et al. Effect of cardiopulmonary bypass on regional antibiotic penetration into lung tissue. Antimicrob. Agents Chemother. 2013, 57:2996-3002.
63. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007, 153:917-923.
64. James C.E., et al. Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections. ISME J. 2015, 9:1391-1398.
65. Kummerli R. Cheat invasion causes bacterial trait loss in lung infections. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:10577-10578.
66. Jiricny N., et al. Loss of social behaviours in populations of Pseudomonas aeruginosa infecting lungs of patients with cystic fibrosis. PLoS ONE 2014, 9:e83124.
67. Brown S.P., et al. Social evolution in micro-organisms and a Trojan horse approach to medical intervention strategies. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2009, 364:3157-3168.
68. Leggett H.C., et al. War and peace: social interactions in infections. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2014, 369:20130365.
69. Fothergill J.L., et al. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti Infect. Ther. 2012, 10:219-235.
70. Hurley M.N., et al. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur. Respir. J. 2012, 40:1014-1023.
71. Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int. J. Med. Microbiol. 2010, 300:584-593.
72. Rumbaugh K.P., et al. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect. Immun. 1999, 67:5854-5862.
73. Lau G.W., et al. Pseudomonas aeruginosa pyocyanin is critical for lung infection in mice. Infect. Immun. 2004, 72:4275-4278.
74. Jimenez P.N., et al. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 2012, 76:46-65.
75. Jain M., et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J. Clin. Microbiol. 2004, 42:5229-5237.
76. Lee J., Zhang L. The hierarchy quorum sensing network in Pseudomonas aeruginosa. Protein Cell 2015, 6:26-41.
77. Mulcahy H., et al. Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation. Infect. Immun. 2008, 76:632-638.
78. Fothergill J.L., et al. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat. Commun. 2014, 5:4780.
79. West S.A., et al. Social evolution theory for microorganisms. Nat. Rev. Microbiol. 2006, 4:597-607.
80. Dumas Z., Kummerli R. Cost of cooperation rules selection for cheats in bacterial metapopulations. J. Evol. Biol. 2012, 25:473-484.
81. Griffin A.S., et al. Cooperation and competition in pathogenic bacteria. Nature 2004, 430:1024-1027.
82. Andersen S.B., et al. Long-term social dynamics drive loss of function in pathogenic bacteria. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:10756-10761.
83. Feil E.J., et al. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J. Bacteriol. 2004, 186:1518-1530.
84. Andrews J.M., et al. BSAC standardized disc susceptibility testing method (version 10). J. Antimicrob. Chemother. 2011, 66:2726-2757.